Clinicopathological features such as O6-methylguanine (O6-MeG)-DNA methyltransferase (MGMT) promoter methylation status (58) and oncogenic mutations (59) are known to influence GBM progression and patient’s prognosis. Here, MGMT is linked to glioblastoma.